Acute Myeloid Leukemia, in Relapse Clinical Trial
Official title:
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML) subjects.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | December 3, 2033 |
Est. primary completion date | August 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female subjects 18 years of age or older 2. Subjects with active acute myeloid leukemia (AML) with no available curative treatment options using currently available therapies. Specifically: 1. AML that has not achieved a complete remission or morphologic leukemia free state by ELN criteria (Döhner et al., 2017 Blood, 129(4):424-447); partial remission or refractory disease (including primary refractory) are eligible. Or: 2. AML relapsed following allogeneic stem cell transplantation (including MDS evolved to AML post-allogeneic stem cell transplantation). Note: morphologic relapse is not required; persistent/recurrent disease-associated molecular, phenotypic or cytogenetic abnormalities (measurable residual disease, MRD) at any time after allogeneic HCT is eligible 3. Subjects with relapsed disease after prior transplant must meet one of the following: a. Subjects with relapsed disease after prior allogeneic HCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and i. Have no residual donor cells (by STR analysis on 2 occasions separated by at least 1 month), OR: ii. Donor cells are present but there is no active GVHD (>Gr II), subject does not require systemic immunosuppression and is more than 3 months from transplant, and at least 1 month off GVHD prophylaxis. b. Subjects with relapsed disease after prior autologous or syngeneic HCT will be eligible if they meet all other inclusion criteria and it has been more than 3 months from transplant. 4. Subjects must have a suitable stem cell donor available who may donate cells in the event the subject needs to undergo an allogeneic HCT. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria; donors must be fully cleared to proceed as the donor. 5. Satisfactory organ functions: 1. Creatinine = 1.6 mg/dl 2. ALT/AST must be =5 x upper limit of normal unless related to disease 3. Direct bilirubin or total bilirubin < 2.0mg/dl, unless subject has Gilbert's syndrome (=3.0 mg/dL); 4. Left ventricular ejection fraction = 40% as confirmed by ECHO/MUGA 6. ECOG Performance status 0-2. 7. Written informed consent is given. 8. No contraindications for leukapheresis. 9. Subjects of reproductive potential must agree to use acceptable birth control methods (as described in protocol Section 4.3). Exclusion Criteria: 1. Pregnant or lactating (nursing women) women. 2. Patients with relapsed AML with t(15:17). 3. HIV infection. 4. Active hepatitis B or hepatitis C infection. 5. Concurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary. For additional details regarding use of steroids while on study, please see Section 5.5. 6. Any uncontrolled active medical disorder that would preclude participation as outlined. 7. Subjects with signs or symptoms indicative of CNS involvement. A CNS evaluation should be performed as clinically appropriate to rule out CNS involvement. 8. Known history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40). 9. Class III/IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 3). 10. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatment. 11. Subjects with clinically apparent arrhythmia, or arrhythmias that are not stable on medical management, within 2 weeks of the Screening/Enrollment visit. 12. Patients with any prior history of myeloproliferative neoplasm. 13. Patients with the JAK2 V617F mutation by PCR or next generation sequencing. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety profile of CART123 cells by monitoring the frequency and severity of adverse events assessed by the National Cancer Institute (NCI) - Common Toxicity Criteria (v5.0) | Assess the safety of CART123 cells in AML subjects following lymphodepletion with cyclophosphamide + fludarabine. | 5 years | |
Primary | Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility. | Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility. | 5 year | |
Secondary | Estimation of CART123 efficacy by evaluation of OS and PFS of subjects at protocol defined intervals which receive at least one infusion of CART123 cells | Estimate the efficacy of at least 1 dose of CART123 cells in AML subjects | 15 years | |
Secondary | Overall Survival (OS) as percent of subjects surviving at protocol defined time points. | Overall survival (OS) and progression-free survival (PFS) | 15 years | |
Secondary | Progression-free survival (PFS) as percent of subjects surviving without disease progression at protocol defined time points | 15 years | ||
Secondary | Duration of response (DOR) | Duration of response (DOR) | 15 years | |
Secondary | Necessity of rescue bone marrow transplant | Need for rescue allogeneic hematopoietic cell transplantation (alloHCT) | 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02204085 -
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT06125652 -
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05105152 -
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
|
Phase 1 | |
Recruiting |
NCT05597306 -
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT04898894 -
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05546580 -
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
|
Phase 1 | |
Recruiting |
NCT03957915 -
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
|
Early Phase 1 | |
Recruiting |
NCT05317403 -
Venetoclax to Augment Epigenetic Modification and Chemotherapy
|
Phase 1 | |
Recruiting |
NCT04867928 -
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT04402541 -
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Not yet recruiting |
NCT04716452 -
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05211570 -
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT03690154 -
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
|
Phase 1 | |
Not yet recruiting |
NCT05854966 -
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Not yet recruiting |
NCT06459024 -
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
|
||
Recruiting |
NCT05735184 -
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
|
Phase 1 | |
Recruiting |
NCT05124288 -
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
|
||
Recruiting |
NCT05506332 -
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05949125 -
Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123
|
Phase 1 | |
Recruiting |
NCT06128044 -
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 |